123_CD Alliance_NNP UniChem_NNP Plc_NNP N_NNP PRINCIPAL_NNP SUBSIDIARY_NNP UNDERTAKINGS_NNP The_DT principal_JJ subsidiary_NN undertakings_NNS of_IN Alliance_NNP UniChem_NNP Plc_NNP ,_, all_DT of_IN which_WDT were_VBD indirectly_RB held_VBN ,_, were_VBD :_: Interest_NN in_IN ordinary_JJ share_NN capital_NN and_CC Country_NN of_IN Country_NN of_IN voting_NN rights_NNS operation_NN incorporation_NN Main_NNP activity_NN Northern_NNP Europe_NNP Wholesale_JJ UniChem_NNP Limited_NNP 100_CD %_NN UK_NNP UK_NNP pharmaceutical_JJ wholesaler_NN Interpharm_NNP B._NNP V._NNP 100_CD %_NN The_DT Netherlands_NNPS The_DT Netherlands_NNP pharmaceutical_JJ wholesaler_NN Alliance_NNP UniChem_NNP CZ_NNP Spo_NNP 97.1_CD %_NN Czech_JJ Republic_NNP Czech_JJ Republic_NNP pharmaceutical_JJ wholesaler_NN Holtung_NNP A._NNP S._NNP 100_CD %_NN Norway_NNP Norway_NNP pharmaceutical_JJ wholesaler_NN Southern_NNP Europe_NNP Wholesale_JJ Alliance_NNP Sant_NNP S._NNP A._NNP 99.8_CD %_NN France_NNP France_NNP pharmaceutical_JJ wholesaler_NN Alleanza_NNP Salute_NNP Italia_NNP SpA_NNP 100_CD %_NN Italy_NNP Italy_NNP pharmaceutical_JJ wholesaler_NN and_CC holding_VBG company_NN Safa_NNP Galenica_NNP S._NNP A._NNP 99.2_CD %_NN Spain_NNP Spain_NNP pharmaceutical_JJ wholesaler_NN Alloga_NNP S._NNP A._NNP 100_CD %_NN Europe_NNP Luxembourg_NNP holding_VBG company_NN for_IN a_DT number_NN of_IN pre-wholesalers_NNS Retail_NNP E._NNP Moss_NNP Limited_NNP 100_CD %_NN UK_NNP UK_NNP retail_JJ pharmacy_NN operator_NN Alliance_NNP UniChem_NNP Norge_NNP A._NNP S._NNP 100_CD %_NN Norway_NNP Norway_NNP retail_JJ pharmacy_NN operator_NN fide_NN Vier_NNP Vijzels_NNP B._NNP V._NNP 100_CD %_NN The_DT Netherlands_NNPS The_DT Netherlands_NNP retail_JJ pharmacy_NN operator_NN As_IN permitted_VBN by_IN section_NN 231_CD 5_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ,_, only_RB principal_JJ undertakings_NNS are_VBP shown_VBN ._.
A_DT complete_JJ list_NN of_IN all_DT subsidiary_NN undertakings_NNS is_VBZ filed_VBN with_IN the_DT Companys_NNP annual_JJ return_NN ._.
O_NNP PRINCIPAL_NNP ASSOCIATED_VBD UNDERTAKINGS_NNS The_DT principal_NN associated_VBN undertakings_NNS of_IN Alliance_NNP UniChem_NNP Plc_NNP are_VBP set_VBN out_RP in_IN the_DT table_NN below_IN ._.
Except_IN for_IN 25_CD %_NN of_IN the_DT interest_NN in_IN Hedef_NNP Alliance_NNP Holding_NNP A._NNP S._NNP these_DT were_VBD indirectly_RB held_VBN ._.
Interest_NN in_IN ordinary_JJ share_NN capital_NN and_CC Country_NN of_IN Country_NN of_IN voting_NN rights_NNS operation_NN incorporation_NN Main_NNP activity_NN 1_CD Alliance_NNP UniChem_NNP Farmacutica_NNP S._NNP A._NNP 49_CD %_NN Portugal_NNP Portugal_NNP pharmaceutical_JJ wholesaler_NN Andreae-Noris_NNP Zahn_NNP AG_NNP 29.99_CD %_NN Germany_NNP Germany_NNP pharmaceutical_JJ wholesaler_NN 2_CD Galenica_NNP A._NN G._NNP 25.5_CD %_NN Switzerland_NNP Switzerland_NNP pharmaceutical_JJ wholesaler_NN Hedef_NNP Alliance_NNP Holding_NNP A._NNP S._NNP 50_CD %_NN Turkey_NNP Turkey_NNP pharmaceutical_JJ wholesaler_NN Pharmapartners_NNP B._NNP V._NNP 40_CD %_NN The_DT Netherlands_NNPS The_DT Netherlands_NNP pharmaceutical_JJ software_NN UniDrug_NNP Distribution_NN Group_NNP Limited_NNP 50_CD %_NN United_NNP Kingdom_NNP United_NNP Kingdom_NNP pre-wholesaler_JJ Unifarma_NNP Distribuzione_NNP S._NNP r._NNP l._VBD 36_CD %_NN Italy_NNP Italy_NNP pharmaceutical_JJ wholesaler_NN 1_CD The_NNP Group_NNP previously_RB owned_VBD 100_CD %_NN of_IN the_DT ordinary_JJ share_NN capital_NN of_IN Alliance_NNP UniChem_NNP Farmacutica_NNP S._NNP A._NN ._.
51_CD %_NN of_IN the_DT ordinary_JJ share_NN capital_NN was_VBD disposed_VBN of_IN during_IN the_DT year_NN ._.
2_CD All_DT shares_NNS have_VBP the_DT same_JJ voting_NN rights_NNS ,_, but_CC no_DT shareholder_NN may_MD exercise_VB more_JJR than_IN 20_CD %_NN of_IN the_DT votes_NNS ._.
P_NNP CONTINGENT_NNP LIABILITIES_NNP The_NNP Group_NNP offers_VBZ its_PRP$ UK_NNP wholesale_JJ customers_NNS access_NN to_TO long_JJ term_NN financing_NN for_IN their_PRP$ pharmacy_NN businesses_NNS through_IN financing_VBG arrangements_NNS developed_VBN by_IN the_DT Group_NNP with_IN its_PRP$ banks_NNS ._.
The_DT Company_NN supports_VBZ these_DT arrangements_NNS through_IN the_DT provision_NN of_IN guarantees_NNS ,_, which_WDT at_IN 31_CD December_NNP 2005_CD amounted_VBD to_TO 19.6_CD million_CD 2004_CD 18.6_CD million_CD ._.
